Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Taxotere (Docetaxel) Plus Adriamycin (Doxorubicin) and Prednisone (TAP) in Hormone-Refractory Prostate Cancer

NCT00416533 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT00416533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00416533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Taxotere (Docetaxel) Plus Adriamycin (Doxorubicin) and Prednisone (TAP) in Hormone-Refractory Prostate Cancer
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2004
Completion date
Not reported
Enrollment
47 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer